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Complete response of skull base inverted papilloma to
chemotherapy: Case report
Edward C. Kuan, M.D., M.B.A.,1 John W. Frederick, M.D.,1 Miguel F. Palma Diaz, M.D.,2
Dean W. Lim, M.D.,3 and Jeffrey D. Suh, M.D.1
ABSTRACT
Background: Inverted papilloma (IP) is the most common benign sinonasal neoplasm. Endoscopic techniques, improved
understanding of pathophysiology, and novel surgical approaches have allowed rhinologists to treat IPs more effectively, with
surgery being the mainstay of therapy. Frontal sinus IP poses a challenge for surgical therapy due to complex anatomy and
potentially difficult surgical access.
Objectives: We reported a unique case of a massive frontal sinus IP that presented with intracranial and orbital extension,
with near resolution after chemotherapy.
Methods: A retrospective case review of a patient with a frontal sinus IP treated at a tertiary academic medical center.
Results: A 75-year-old male patient presented with nasal obstruction, purulent nasal discharge, and a growing left
supraorbital mass. Endoscopy demonstrated a mass that filled both frontal and ethmoid sinuses, with orbital invasion. There
also was substantial erosion of the posterior table, which measured 1.73  1.40 cm. A biopsy specimen demonstrated IP with
carcinoma in situ. The patient was deemed unresectable on initial evaluation and, subsequently, underwent chemotherapy
(carboplatin and paclitaxel). The tumor had a dramatic response to chemotherapy, and the patient elected for definitive surgery
to remove any residual disease. During surgery, only a small focus of IP was found along the superior wall of the frontal sinus.
No tumor was found elsewhere, including at the site of skull base erosion. The final pathology was IP without carcinoma in
situ or dysplasia.
Conclusion: This was the first reported case of chemotherapeutic “debulking” of IP, which facilitated surgical resection,
despite substantial intracranial and orbital involvement. Although nearly all IPs can be treated surgically, rare cases, such as
unresectable tumors, may benefit from systemic chemotherapy.
(Allergy Rhinol 8:e105–e108, 2017; doi: 10.2500/ar.2017.8.0201)
Inverted papilloma (IP) is the most common benignneoplasm of the sinonasal tract. With novel en-
doscopic techniques and an improved understand-
ing of its pathophysiology, IP is now effectively
managed through surgery, with recurrence rates as
low as 5–10%.1 Standard surgical therapy entails
debulking disease until the site of attachment and
obtaining an adequate deep margin (including over-
lying bone, if any).2 Although histologically benign,
if left alone, IPs have a propensity to undergo ma-
lignant transformation, the rate of which is estimated
to be between 5 and 15%.3
Adjunctive therapies, such as radiation and chemo-
therapy, have traditionally played a limited role in the
management of IP and are generally not considered
first-line therapy. Indications to consider these thera-
pies generally include multiple recurrences, locally ad-
vanced and/or unresectable disease, positive margins,
IP with malignant transformation, and poor surgical
candidates. Of these tumor characteristics, chemother-
apy is truly only considered when there is a suspicion
for malignant transformation and, overall, is uncom-
monly used as a treatment option. We reported a case
of a patient with a massive frontal sinus IP with intra-
cranial and orbital extension, initially thought to have
malignant disease, with a dramatic response to chemo-
therapy. This report was approved by the institutional
review board of the University of California, Los An-
geles, California.
CASE PRESENTATION
A 75-year-old healthy male patient presented to the
clinic at a tertiary cancer center with nasal obstruction,
purulent nasal discharge, and a growing left supra-
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and intraorbital mass over the past 7 months. There
was an associated 15-lb (6.8-kg) weight loss. He had a
nasal biopsy performed outside of the hospital, which
was read as IP with squamous cell carcinoma in situ.
Nasal endoscopy revealed a large polypoid nasal mass
that filled both the frontal and ethmoid sinuses, with
apparent left orbital invasion. Computed tomography
(Fig. 1) and magnetic resonance imaging (Fig. 2) of the
sinuses was obtained and showed the mass extending
posteriorly within the frontal sinus, with associated
mucocele formation, which eroded the posterior table
over an area of 1.73  1.40 cm. Of note, the patient had
a 60 pack-year smoking history and consumed six al-
coholic drinks per week over the past 30 years.
He was initially deemed by the treating team to have
unresectable disease, with the large mass being unable
to be selectively encompassed by radiation therapy. As
such, he elected chemotherapy with carboplatin (306.3
mg per cycle) and paclitaxel (542.4 mg per cycle),
which he completed over 6 weeks (four cycles). As
treatment progressed, although he had adverse effects
from the chemotherapy, his sinonasal symptoms im-
proved and his left supraorbital swelling began to re-
gress (Fig. 3).
He was then referred to a tertiary rhinology clinic,
where he elected for definitive surgical management to
remove any residual disease. A repeated preoperative
computed tomography demonstrated marked shrink-
age of the mass (Fig. 4). An endoscopic modified Lo-
throp procedure (Draf III) was performed, during
which only a small focus of IP was found along the
superior wall of the left frontal sinus (Fig. 5). Of note,
Figure 1. Pretreatment computed tomography of the sinuses demonstrates extensive disease filling the frontal and ethmoid sinuses, with
mucocele formation, leading to left intraorbital extension and erosion of the posterior table of the frontal sinus.
Figure 2. Pretreatment magnetic resonance imaging of the sinuses once again demonstrates the extensive left-sided disease with associated
mucocele.
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there was a large area of posterior table erosion, with
dural pulsations visible through the mucosa and no
intervening bony layer, although there was no frank
intracranial connection. The final pathology results
showed only IP without squamous cell carcinoma in
situ or dysplasia. The patient had been followed up
every 1–2 months as an outpatient and remained re-
currence free at 1 year after surgery, with good overall
functional status after recovery from chemotherapy.
DISCUSSION
Most IP cases can be effectively treated, even cured,
by endoscopic sinus surgery alone. In contrast, previ-
ous reports indicate that squamous cell carcinoma that
arises from IP has a guarded prognosis, of 63% sur-
vival at 3 years.4 This particular patient was treated
with chemotherapy because the initial biopsy result
was suggestive of malignant transformation. Inciden-
tally, it achieved a “medical debulking” phenomenon,
which facilitated his subsequent surgery (e.g., de-
creased disease burden, decreased blood loss, im-
proved access). Although extremely rare for patients
with IP in difficult-to-access areas (e.g., lateral frontal
sinus), extensive disease, or malignant transformation,
neoadjuvant systemic chemotherapy may improve sur-
gical access, which allowed for a chance of a cure.
There is at least some interest in identifying novel
chemotherapeutic agents for the management of IP,
with photodynamic therapy showing some efficacy.5
Adriaensen et al.6 suggested efficacy in topical appli-
cation of 5-fluorouracil, a nucleoside synthesis inhibi-
tor, over sites where complete mucoperiosteum and
Figure 3. Before (left), during (6
weeks after initiation of therapy) (cen-
ter), and after (2 months after comple-
tion of therapy) (right) chemotherapy
pictures of the patient (used with
written permission), with near-com-
plete resolution of the left supraorbital
swelling.
Figure 4. Postchemotherapy computed tomography of the sinuses
demonstrates near resolution of the left frontal sinus mass; areas of
supraorbital and posterior table dehiscence are evident.
Figure 5. Postoperative endoscopy of the Draf III cavity demon-
strated mucosal healing but no evidence of recurrent disease, with
a visible dehiscence of the posterior table of the frontal sinus.
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bone removal may not be possible. It is critical to weigh
the risks and benefits of chemotherapy with the patient
before deciding on treatment. In this case, carboplatin,
an alkylating agent, is associated with myelosuppres-
sion and thus an elevated risk of opportunistic infec-
tions, whereas paclitaxel, a tubulin-targeting drug, is
frequently associated with peripheral neuropathy.
Both drugs may also cause systemic toxicity, such as
nausea and vomiting, hair loss, and diarrhea.
As we begin to understand more about the patho-
physiology of IP, surgical strategies have evolved to
address this disease process. Specifically, once the tu-
mor has been debulked and the site of attachment is
identified, removal of this site, followed by drilling,
cauterization, or excision of the underlying bone is
now considered standard of care.2 Primary cases have
a higher rate of cure because revision cases are often
associated with distorted anatomic landmarks, multi-
ple sites of attachments, and tumor seeding.7 IPs with
sites of attachments in the frontal and sphenoid sinuses
pose special challenges due to the proximity of the
skull base. For frontal sinus IPs, medial and posterior
wall IPs may often be completely removed via a stan-
dard unilateral endoscopic frontal sinusotomy,
whereas those with broader attachments or multifocal
involvement may be best accessed via a modified en-
doscopic Lothrop procedure. For extremely extensive
frontal sinus IPs, a frontal sinus trephination or osteo-
plastic flap procedure may be indicated for complete
removal of disease. However, the posterolateral wall of
the sphenoid sinus houses the optic nerve and carotid
arteries, and complete bone removal overlying these
structures is infeasible. For this reason, sphenoid sinus
IP has a high rate of recurrence (14.6%),8 and, often-
times, the decision is made to perform a subtotal re-
section with judicious follow up and surveillance as
opposed to risk injury to the underlying neurovascular
structures.
Similar to but more spatially selective than chemo-
therapy is the potential value of radiation therapy in
treating IPs. In contrast to chemotherapy, radiation
allows for selective targeting of primary tumor sites,
although local toxicity to surrounding normal struc-
tures must be taken into consideration before treat-
ment. This is especially true with the advent of newer
technologies, such as intensity modulation or stereo-
tactic guidance, in which concentrated radiation doses
may be delivered to a targeted area with precision and
spatial selectivity. For instance, Hug et al.9 reported
that 7 of 7 patients (100%) with IP and 15 of 18 of
patients with IP and with associated invasive carci-
noma (83%) achieved long-term recurrence-free sur-
vival after primary or adjuvant radiation therapy.
There are other reports with similar results, with good
local control rates.10 However, the unifying theme of
advocating for the use of radiation therapy is only in
the context of failed surgical management, especially in
patients with unresectable, multiply recurrent, or ma-
lignant disease.
CONCLUSION
Although not without its comorbidities and medical
and functional sequelae, chemotherapy may be consid-
ered in rare cases of unresectable IP. We reported, to
our knowledge, the first case in the literature of a
patient who, after receiving treatment, has performed
remarkably well and remained free of recurrent dis-
ease today.
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